BIOVERATIV INC(NASDAQ:BIVV) stock News

BIVV Latest News, Press Relases and Analysis

All

Press Releases

6 years ago - By: Bloomberg

Swiss Man Charged in $4.7 Million Sanofi Insider Scheme

7 years ago - By: Bloomberg - Mentions: SPPI SPPI

Spectrum Pharma Is Weighing a Sale

7 years ago - By: Investor's Business Daily - Mentions: LLY MRK BMY ARMO ...

Lilly Is Spending $1.6 Billion To 'Leapfrog' Merck, Bristol — Will It Work?

7 years ago - By: Investor's Business Daily - Mentions: AGN SHPG CELG SNY ...

Allergan Bows Out Of Shire Battle Against Takeda After Stock Slammed

7 years ago - By: Investor's Business Daily - Mentions: SHPG AGN CELG SNY ...

Allergan Reportedly Enters Fray To Buy Shire, Rivaling Takeda

7 years ago - By: StockNews.com

Bioverativ Inc. (BIVV): Earnings News

7 years ago - By: Investor's Business Daily - Mentions: GILD JNJ NVO SHPG ...

These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status

7 years ago - By: StockNews.com

Bioverativ Inc. (BIVV): Neutral Rating Reiterated

7 years ago - By: Analyst Ratings

Bioverativ Inc Gets a Hold Rating from William Blair

7 years ago - By: Investor's Business Daily - Mentions: AAPL AMZN GE AMTD ...

These Are The Top Stocks That Retail Investors Bought And Sold In A Wild February

7 years ago - By: Benzinga - Mentions: AAPL AMZN GILD MSFT ...

Investor Movement Index February Summary

7 years ago - By: Bioverativ Inc.

Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease

7 years ago - By: S&P Dow Jones Indices - Mentions: FNSR IPGP NYMT SNI ...

IPG Photonics Set to Join S&P 500; ALLETE and LendingTree to Join S&P MidCap 400; New York Mortgage Trust, Global Net Lease and Finisar to Join S&P SmallCap 600

7 years ago - By: TalkMarkets - Mentions: CELG JUNO SNY CNCR ...

Biotech Crushing the Market: Best ETFs & Stocks YTD

7 years ago - By: TalkMarkets - Mentions: QQQ DIA IWM SPY ...

Biotechs: Still Well Placed For More Gains

7 years ago - By: StockNews.com

Bioverativ Inc. (BIVV): Hedge Fund News

7 years ago - By: Bioverativ Inc.

Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A

7 years ago - By: Bioverativ Inc.

Bioverativ Reports Fourth Quarter and Full Year 2017 Performance

7 years ago - By: Benzinga - Mentions: BIDU FOSL IOSP SINA ...

Earnings Scheduled For February 13, 2018

7 years ago - By: The Motley Fool - Mentions: SNY

Here's How Sanofi Hopes to Avoid the Patent Cliff

7 years ago - By: InvestorPlace - Mentions: SNY CELG SRNE JNCE ...

Biotech M&A: Sanofi SA (ADR) Inks 2nd Multi-Billion Dollar Deal in a Week

7 years ago - By: The Motley Fool - Mentions: SNY

Big Biotech Is Bustling With Buyouts

7 years ago - By: InvestorPlace - Mentions: GILD BIIB AMGN PFE ...

5 Biotech and Pharmaceutical Stocks Going Bonkers

7 years ago - By: The Law Offices of Vincent Wong

The Law Offices of Vincent Wong Notifies Investors of an Investigation of Bioverativ Inc. in Connection with the Sale of the Company to Sanofi

7 years ago - By: InvestorPlace - Mentions: LLY CELG JUNO SNY ...

Why Investors Should Stay Long Eli Lilly and Co Stock

7 years ago - By: WeissLaw LLP

WeissLaw LLP Investigates Bioverativ Inc. Acquisition

7 years ago - By: StockNews.com

Bioverativ Inc. (BIVV): Neutral Rating Reiterated

7 years ago - By: Analyst Ratings - Mentions: PBYI

Analysts Offer Insights on Healthcare Companies: Puma Biotechnology (NYSEArca: PBYI) and Bioverativ Inc (NASDAQ: BIVV)

7 years ago - By: TalkMarkets - Mentions: D SCG SSNC DST ...

2018 Could Be "The Year of M&A"

7 years ago - By: Rigrodsky & Long, P.A.

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Bioverativ Inc. Buyout

7 years ago - By: StockNews.com

Bioverativ Inc. (BIVV): Neutral Rating Reiterated

7 years ago - By: Levi & Korsinsky, LLP

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders

7 years ago - By: StockNews.com

BIOVERATIV INC (BIVV) Stock News

BIVV Latest News, Press Relases and Analysis

Swiss Man Charged in $4.7 Million Sanofi Insider Scheme

Spectrum Pharma Is Weighing a Sale

Lilly Is Spending $1.6 Billion To 'Leapfrog' Merck, Bristol — Will It Work?

Allergan Bows Out Of Shire Battle Against Takeda After Stock Slammed

Allergan Reportedly Enters Fray To Buy Shire, Rivaling Takeda

Bioverativ Inc. (BIVV): Earnings News

These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status

Bioverativ Inc. (BIVV): Neutral Rating Reiterated

Bioverativ Inc Gets a Hold Rating from William Blair

These Are The Top Stocks That Retail Investors Bought And Sold In A Wild February

Investor Movement Index February Summary

Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease

IPG Photonics Set to Join S&P 500; ALLETE and LendingTree to Join S&P MidCap 400; New York Mortgage Trust, Global Net Lease and Finisar to Join S&P SmallCap 600

Biotech Crushing the Market: Best ETFs & Stocks YTD

Biotechs: Still Well Placed For More Gains

Bioverativ Inc. (BIVV): Hedge Fund News

Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A

Bioverativ Reports Fourth Quarter and Full Year 2017 Performance

Earnings Scheduled For February 13, 2018

Here's How Sanofi Hopes to Avoid the Patent Cliff

Biotech M&A: Sanofi SA (ADR) Inks 2nd Multi-Billion Dollar Deal in a Week

Big Biotech Is Bustling With Buyouts

5 Biotech and Pharmaceutical Stocks Going Bonkers

The Law Offices of Vincent Wong Notifies Investors of an Investigation of Bioverativ Inc. in Connection with the Sale of the Company to Sanofi

Why Investors Should Stay Long Eli Lilly and Co Stock

WeissLaw LLP Investigates Bioverativ Inc. Acquisition

Bioverativ Inc. (BIVV): Neutral Rating Reiterated

Analysts Offer Insights on Healthcare Companies: Puma Biotechnology (NYSEArca: PBYI) and Bioverativ Inc (NASDAQ: BIVV)

2018 Could Be "The Year of M&A"

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Bioverativ Inc. Buyout

Bioverativ Inc. (BIVV): Neutral Rating Reiterated

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders

Bioverativ Inc. (BIVV): Upgrade News